To speed up the discovery of innovative biotherapeutics candidates with the potential to address significant unmet medical needs, we have established global R&D partnerships in Europe, China, and globally.

Angel Therapeutics will seek collaboration/in and out-licensing partners (global and reginal licensing agreements) for the assets at early stage, preclinical stage, and upon completion of IND-enabling safety studies, Phase 1 or Phase 2 trials. Selected partners will have expertise to contribute to the later stages of development and/or commercialization of the molecules, and to maximize the potential of the assets.
To learn more about how you might partner with Angel Therapeutics, please contact us at